We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). | Treatment decisions clinical outcomes and pharmacoeconomics in the treatment of patients with EGFR mutated stage III IV NSCLC in Germany An observational study